Favorable five-year survival reported for patients with advanced cancer treated with the immunotherapy

(Johns Hopkins Medicine) A research team led by experts at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center reports favorable five-year survival rates from the first multidose clinical trial of the immunotherapy drug nivolumab (anti-PD-1) as a treatment for patients whose previous therapies failed to stem their advanced melanoma, renal cell carcinoma (RCC) or non-small-cell lung cancer (NSCLC).

https://www.eurekalert.org/pub_releases/2019-07/jhm-ff072419.php

Source: EurekAlert! - Medicine and Health - July 25, 2019 Category: International Medicine & Public Health Source Type: news